The Endocannabinoid 2-arachidonoylglycerol Mediates D1 and D2 Receptor Cooperative Enhancement of Rat Nucleus Accumbens Core Neuron Firing
Overview
Authors
Affiliations
Many motivated and addiction-related behaviors are sustained by activity of both dopamine D1- and D2-type receptors (D1Rs and D2Rs) as well as CB1 receptors (CB1Rs) in the nucleus accumbens (NAc). Here, we use in vitro whole-cell patch-clamp electrophysiology to describe an endocannabinoid (eCB)-dopamine receptor interaction in adult rat NAc core neurons. D1R and D2R agonists in combination enhanced firing, with no effect of a D1R or D2R agonist alone. This D1R+D2R-mediated firing increase required CB1Rs, since it was prevented by the CB1R antagonists AM251 and Rimonabant. The D1R+D2R firing increase also required phospholipase C (PLC), the major synthesis pathway for the eCB 2-arachidonoylglycerol (2-AG) and one of several pathways for anandamide. Further, inhibition of 2-AG hydrolysis with the monoglyceride lipase (MGL) inhibitor JZL184 allowed subthreshold levels of D1R+D2R receptor agonists to enhance firing, while inhibition of anandamide hydrolysis with the fatty acid amide hydrolase (FAAH) inhibitors URB597 or AM3506 did not. Filling the postsynaptic neuron with 2-AG enabled subthreshold D1R+D2R agonists to increase firing, and the 2AG+D1R+D2R increase in firing was prevented by a CB1R antagonist. Also, the metabotropic glutamate receptor 5 (mGluR5) blocker MPEP prevented the ability of JZL184 to promote subthreshold D1R+D2R enhancement of firing, while the 2-AG+D1R+D2R increase in firing was not prevented by the mGluR5 blocker, suggesting that mGluR5s acted upstream of 2-AG production. Thus, our results taken together are consistent with the hypothesis that NAc core eCBs mediate dopamine receptor (DAR) enhancement of firing, perhaps providing a cellular mechanism underlying the central role of NAc core D1Rs, D2Rs, CB1Rs, and mGluR5s during many drug-seeking behaviors.
Perez-Morales M, Espinoza-Abad R, Garcia-Garcia F Pharmaceuticals (Basel). 2025; 18(2).
PMID: 40006078 PMC: 11860062. DOI: 10.3390/ph18020266.
Kondev V, Najeed M, Loomba N, Brown J, Winder D, Grueter B Proc Natl Acad Sci U S A. 2023; 120(34):e2300585120.
PMID: 37590414 PMC: 10450650. DOI: 10.1073/pnas.2300585120.
Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings.
Kesner A, Lovinger D J Neurochem. 2021; 157(5):1674-1696.
PMID: 33891706 PMC: 9291571. DOI: 10.1111/jnc.15369.
Rahimi J, Zendehdel M, Khodadadi M Amino Acids. 2021; 53(3):461-470.
PMID: 33649971 DOI: 10.1007/s00726-021-02963-3.
Canseco-Alba A, Rodriguez-Manzo G Front Behav Neurosci. 2019; 13:184.
PMID: 31474840 PMC: 6702338. DOI: 10.3389/fnbeh.2019.00184.